Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (2238)	10/8/1999 12:36:00 PM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

-----Original Message----- From: Linda R. Watkins <lwatkins@psych.colorado.edu> Cc: lwatkins@psych.colorado.edu <lwatkins@psych.colorado.edu> Date: Friday, October 08, 1999 11:10 AM Subject: Re: IL-1b >Sure! IL1 receptor antagonist, soluble receptors for IL1, etc are already >in human clinical trials. Same for TNF. Also, there are drugs being >tested in animals that disrupt various aspects of synthesis of the >proinflammatory cytokines. So.... could be a very interesting next few >years for drug development! cheers - L > > >>Hi, >> >>I just read the abstract on Dynamic regulation of the proinflammatory >>cytokine, interleukin-1beta: molecular biology for non-molecular biologists. >> >>Do you believe that IL-1beta research will ever result in a drug or vaccine? >> >> >>Thanks, >> >>Walter Morton > > > >------------------------------------------------------------------------ >Linda R.Watkins, Professor Department of Psychology >tel: +1 (303) 492-7034 Campus Box 345 >fax: +1 (303) 492-2967 University of Colorado >lwatkins@psych.colorado.edu Boulder, Colorado 80309-0345 USA >------------------------------------------------------------------------ >